News

News

Viglya wishes to establish transparent and open communication with its stakeholders. This section offers new and updated information regarding the company and the life science sector.

10.03.2014

AEMPS: Solicitudes de autorización de comercialización de medicamentos de uso humano. Monográfico de bases legales

Sorry, this entry is only available in Español.

LinkedIn1Twitter1Facebook0Google+0tumblr

Comments are closed.

EMA: Draft proposal for an addendum, on transparency, to the “Functional specifications for the European Union portal and EU database to be audited”
EMA: New international standard to improve safety of medicines
EMA: Public consultation on application of transparency rules of EU Clinical Trial Regulation
UK MHRA: New vice-chair appointed to Commission on Human Medicines
ANSM: Suspension de la mise sur le marché, importation, distribution et utilisation, retrait des dispositifs médicaux fabriqués par la société EUROBAND repreneuse de la société POLLAK, mis sur le marché après le 1er juin 2013
EMA: Europe to boost international cooperation on generics
FDA approves first-of-kind device to treat obesity
ANSM: Finalisation de la réévaluation des médicaments contenant de l’ambroxol ou de la bromhexine, retour d’information sur le PRAC de janvier 2015
FDA Drug Information Update- New Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products
AEMPS: Informe de “Utilización de medicamentos antidepresivos en España durante el periodo 2000-2013″